200 related articles for article (PubMed ID: 35025968)
1. EBV+ tumors exploit tumor cell-intrinsic and -extrinsic mechanisms to produce regulatory T cell-recruiting chemokines CCL17 and CCL22.
Jorapur A; Marshall LA; Jacobson S; Xu M; Marubayashi S; Zibinsky M; Hu DX; Robles O; Jackson JJ; Baloche V; Busson P; Wustrow D; Brockstedt DG; Talay O; Kassner PD; Cutler G
PLoS Pathog; 2022 Jan; 18(1):e1010200. PubMed ID: 35025968
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-positive pyothorax-associated lymphoma expresses CCL17 and CCL22 chemokines that attract CCR4-expressing regulatory T cells.
Higuchi T; Matsuo K; Hashida Y; Kitahata K; Ujihara T; Taniguchi A; Yoshie O; Nakayama T; Daibata M
Cancer Lett; 2019 Jul; 453():184-192. PubMed ID: 30953706
[TBL] [Abstract][Full Text] [Related]
3. Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder.
Takegawa S; Jin Z; Nakayama T; Oyama T; Hieshima K; Nagakubo D; Shirakawa AK; Tsuzuki T; Nakamura S; Yoshie O
Cancer Sci; 2008 Feb; 99(2):296-302. PubMed ID: 18271928
[TBL] [Abstract][Full Text] [Related]
4. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus.
Nakayama T; Hieshima K; Nagakubo D; Sato E; Nakayama M; Kawa K; Yoshie O
J Virol; 2004 Feb; 78(4):1665-74. PubMed ID: 14747532
[TBL] [Abstract][Full Text] [Related]
5. CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.
Kumai T; Nagato T; Kobayashi H; Komabayashi Y; Ueda S; Kishibe K; Ohkuri T; Takahara M; Celis E; Harabuchi Y
Cancer Immunol Immunother; 2015 Jun; 64(6):697-705. PubMed ID: 25754123
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S; Tay JK; Loh CJL; Chu AJM; Yeong JPS; Lim CM; Toh HC
Front Immunol; 2021; 12():734293. PubMed ID: 34956172
[TBL] [Abstract][Full Text] [Related]
7. CCL17 acts as an antitumor chemokine in micromilieu-driven immune skewing.
Li Y; Cao H; Jiang Z; Yan K; Shi J; Wang S; Wang F; Wang W; Li X; Sun N; Liu L; Chen L; Chen Y; Guo R; Song Y
Int Immunopharmacol; 2023 May; 118():110078. PubMed ID: 37001380
[TBL] [Abstract][Full Text] [Related]
8. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease.
Beck A; Päzolt D; Grabenbauer GG; Nicholls JM; Herbst H; Young LS; Niedobitek G
J Pathol; 2001 Jun; 194(2):145-51. PubMed ID: 11400141
[TBL] [Abstract][Full Text] [Related]
9. Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
Kang S; Xie J; Ma S; Liao W; Zhang J; Luo R
Immunobiology; 2010; 215(2):153-62. PubMed ID: 19450895
[TBL] [Abstract][Full Text] [Related]
10. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
11. Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.
Yogo Y; Fujishima S; Inoue T; Saito F; Shiomi T; Yamaguchi K; Ishizaka A
Respir Res; 2009 Aug; 10(1):80. PubMed ID: 19715610
[TBL] [Abstract][Full Text] [Related]
12. [Correlation analysis of the Epstein-Barr virus recruited regulatory T cells in nasopharyngeal carcinoma of immune escape].
Bi P; Wang J; Lu J; Liu X; Wang F; Luo YF; Peng SD; Li XP
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Sep; 52(9):692-697. PubMed ID: 28910895
[No Abstract] [Full Text] [Related]
13. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
[TBL] [Abstract][Full Text] [Related]
14. Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.
Lou H; Fang J; Li P; Zhou W; Wang Y; Fan E; Li Y; Wang H; Liu Z; Xiao L; Wang C; Zhang L
PLoS One; 2015; 10(5):e0126463. PubMed ID: 26020249
[TBL] [Abstract][Full Text] [Related]
15. Surrogate antibodies that specifically bind and neutralize CCL17 but not CCL22.
Santulli-Marotto S; Fisher J; Petley T; Boakye K; Panavas T; Luongo J; Kavalkovich K; Rycyzyn M; Wu B; Gutshall L; Coelho A; Hogaboam CM; Ryan M
Monoclon Antib Immunodiagn Immunother; 2013 Jun; 32(3):162-71. PubMed ID: 23750473
[TBL] [Abstract][Full Text] [Related]
16. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
17. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer.
Mizukami Y; Kono K; Kawaguchi Y; Akaike H; Kamimura K; Sugai H; Fujii H
Int J Cancer; 2008 May; 122(10):2286-93. PubMed ID: 18224687
[TBL] [Abstract][Full Text] [Related]
18. CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.
Maruyama T; Kono K; Izawa S; Mizukami Y; Kawaguchi Y; Mimura K; Watanabe M; Fujii H
Dis Esophagus; 2010 Jul; 23(5):422-9. PubMed ID: 20002703
[TBL] [Abstract][Full Text] [Related]
19. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation.
Osabe M; Tajika T; Tohkin M
J Appl Toxicol; 2018 Feb; 38(2):274-283. PubMed ID: 28949055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
